ROSITEL

Changes to Inflammatory Markers in Hypertensive Diabetic Patients Using an Oral Antidiabetic Medication (ROSIglitazone or Metformin or Glyburide) and an Angiotensin Receptor Blocker (TELmisartan)

Status: Completed

The purpose of the ROSITEL study is to assess the effects of Rosiglitazone, as compared to standard oral therapies for diabetes (Metformin/Sulfonylurea), on inflammatory markers and adipokine levels in diabetic patients using an angiotensin receptor blocker (ARB). We hypothesize that ARB-treated diabetic patients receiving Rosiglitazone will experience greater reductions in vascular inflammation and levels of leptin and resistin, associated with increased Adiponectin levels, compared to a Metformin/Sulfonylurea regimen, and that these benefits will result in part, from greater improvements in insulin sensitivity in the Rosiglitazone group.

Study Design: Randomized open-label, parallel group design

Intervention: Rosiglitazone vs. Metformin/Glyburide

Length of Study: 2 year

Project Start: 2006

Project Completion: Completed

# of Patients: 115

Patient Population: Type 2 DM patients either treatment naïve or on Metformin or any Sulfonylurea

PRESENTATIONS: None available

PUBLICATIONS

Presented at the Canadian Cardiovascular Congress 2010, Scientific Session

Gupta M, Teoh H, Kajil M, Tsigoulis M, Quan A, Braga M, Verma S. Rosiglitazone-based therapy reduces inflammatory biomarkers in diabetic, hypertensive patients compared to a metformin and glyburide based-regimen: The ROSITEL randomized trial. Can J Cardiol. 2010;26(Suppl D):125D

A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. Gupta M, Braga MB , Verma S. Can J Cardiol. 2008 Oct;24(10):e65-9. PMID: 18841263 [PubMed - indexed for MEDLINE]

This study was funded by CCRN through an unrestricted investigator initiated research grant from GlaxoSmithKline Canada Inc.